Emerging molecular approaches to pain therapy.
Williams
M
M
Pharmaceutical Products Division, Abbott Laboratories, DuPont Pharmaceuticals, Illinois, USA. mike.williams@abbott.com
Kowaluk
E A
EA
Arneric
S P
SP
D000322:Adrenergic Agonists / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018679:Cholinergic Agonists / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D018755:GABA Agonists / Q000627:therapeutic use; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017470:Receptors, Glutamate / Q000187:drug effects; D018000:Receptors, Peptide / Q000037:antagonists & inhibitors; D011983:Receptors, Purinergic / Q000187:drug effects
D000322:Adrenergic Agonists; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018679:Cholinergic Agonists; D016207:Cytokines; D018755:GABA Agonists; D006133:Growth Substances; D007473:Ion Channels; D017470:Receptors, Glutamate; D018000:Receptors, Peptide; D011983:Receptors, Purinergic; D009569:Nitric Oxide